



Supplementary figure 8. Luminex assay validation of proteomic (BAG4, IL6ST, VWF, EGFR, and CD44) and glycomic (EGFR and CD44) markers on PRoBE compliant cohort. The controls consisted of serum samples from 168 normal individuals, 159 individuals with low risk colon polyyps and 59 individuals with ulcerative colitis. The cancer samples consisted of serum samples from stage I (114 cases), stage II (155 cases), stage III (147 cases) and stage IV (98 cases) patients. FIU: fluorescence intensity unit. * corresponds to p-value of each case group vs all controls. The dotted lines indicate where there is a change in y-axis scaling.